Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 4Multiple Myeloma 3Lymphoma 3Lung Neoplasms 3Endometrial Neoplasms 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Glioma 1Genital Diseases 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 30fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Tacrolimus 17Mycophenolic Acid 16Methotrexate 16Whole-Body Irradiation 14Etoposide 13Vincristine 12Doxorubicin 12Dexamethasone 11Busulfan 11Cytarabine 10Antilymphocyte Serum 10venetoclax 9Prednisone 9nelarabine 8Rituximab 8Filgrastim 8Cyclosporine 8Calcium Dobesilate 8merphos 7Melphalan 7Radiotherapy 6prednylidene 5deltacortene 5Methylprednisolone 5Azacitidine 5Sirolimus 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × sapanisertib × Clear all
NCT02484430 2025-03-03

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡